Just wondering if anyone else is aboard, as this is my only other Biotech that I'm holding.

For those unfamiliar here is a quick summary

Its in the Cancer Field having just recieved a FDA thumbs up for Thyroid Cancer (Phase 3). Problem is it is going nowhere since approval due to the size of the market 500-700 patients annually in US with an annualized cost of 120K per patient.

Cometriq (aka Cabo) is also showing positive indicators in 5 or 6 other application to other cancers but its shining star seems to be its capability to resolve bone metasticies. Currently undergoing a Phase 3 trial for Prostate cancer which should propel this into the doble digits (currently 4.75). Other trials underway of other compound licencesd out but none nearing the Ph3 finish line.

Quote from Motely Foll article:
"In the company's 2011 annual report, chief executive officer, and medical doctor, Michael Morrissey described the opportunity behind this choice: “The potential is obvious – to date cabozantinib has shown anti-tumor activity in 12 out of 13 tumor types tested, and has induced regression of metastatic or primary tumor lesions in soft tissue, visceral organs, and the brain, and resolution of bone lesions on bone scan.”

Company seemeed like it was for sale, but not sure now as they have enough inccome and cash in the bank to complete the Prostate trials.

OOG